STOCK TITAN

Seres Therapeutics (MCRB) awards 50,000 stock options to director-officer

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Seres Therapeutics, Inc. reported that director and officer Richard N. Kender received a grant of stock options covering 50,000 shares of common stock at an exercise price of $9.13 per share. These options vest in 36 equal monthly installments beginning on March 2, 2026, and are scheduled to expire on March 3, 2036. Following this grant, Kender holds stock options for 50,000 shares directly.

Positive

  • None.

Negative

  • None.
Insider Kender Richard N
Role See Remarks
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) 50,000 $0.00 --
Holdings After Transaction: Stock Option (right to buy) — 50,000 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Options Granted 50,000 shares Stock option grant to Richard N. Kender reported as of transaction date July 8, 2026
Exercise Price $9.13 per share Conversion or exercise price for the 50,000 stock options
Expiration Date March 3, 2036 Scheduled expiration date of the granted stock options
Vesting Period 36 months Options vest in 36 equal monthly installments after March 2, 2026
Post-transaction Option Holdings 50,000 shares Total stock option shares held directly by Richard N. Kender after the grant
Stock Option financial
"The option vests and becomes exercisable in 36 equal monthly installments"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
exercise price financial
"conversion_or_exercise_price: "9.1300""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting commencement date financial
"following the March 2, 2026 vesting commencement date"
The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What did insider Richard N. Kender receive in the latest Form 4 for MCRB?

Richard N. Kender received a stock option grant for 50,000 shares of Seres Therapeutics common stock, with an exercise price of $9.13 per share and expiration on March 3, 2036.

How do the 50,000 Seres Therapeutics (MCRB) options granted to Richard N. Kender vest?

The 50,000 stock options granted to Richard N. Kender vest in 36 equal monthly installments starting from the March 2, 2026 vesting commencement date, gradually becoming exercisable over three years.

What is the exercise price of the options reported in the Seres Therapeutics (MCRB) Form 4?

The options reported for Richard N. Kender have an exercise price of $9.13 per share. They relate to Seres Therapeutics common stock and represent a right to buy 50,000 shares at that price.

When do Richard N. Kender’s Seres Therapeutics (MCRB) options expire?

The reported stock options held by Richard N. Kender are scheduled to expire on March 3, 2036. Any unexercised portion after this date will no longer be exercisable under the grant terms.

How many Seres Therapeutics (MCRB) option shares does Richard N. Kender hold after this transaction?

After the grant, Richard N. Kender holds stock options for 50,000 shares of Seres Therapeutics common stock directly, as reflected in the Form 4’s post-transaction holdings figure.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Kender Richard N

(Last)(First)(Middle)
C/O SERES THERAPEUTICS, INC.
101 CAMBRIDGE PARK DRIVE

(Street)
CAMBRIDGE MASSACHUSETTS 02140

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Seres Therapeutics, Inc. [ MCRB ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
See Remarks
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/08/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$9.1307/08/2026A50,000 (1)03/03/2036Common Stock50,000$050,000D
Explanation of Responses:
1. The option vests and becomes exercisable in 36 equal monthly installments following the March 2, 2026 vesting commencement date.
Remarks:
Interim Chief Executive Officer
/s/ Thomas J. DesRosier, Attorney-in-Fact for Richard N. Kender07/10/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)